TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.

HUGE stock results show that FSD Pharma missed analyst estimates for earnings per share the second quarter of 2024.

It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.

FSD Pharma shares are trading higher Friday after the company provided an update on its investment in Celly Nutrition. Here's a look at what's going on:

FSD Pharma announces share consolidation, rebranding as Quantum BioPharma Ltd., and a new private placement to strengthen market position and meet Nasdaq requirements.

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is planning to consolidate its issued and outstanding class A multiple voting shares and class B subordinate voting shares. The company also has announced a planned name change to Quantum BioPharma Ltd, with a new trading symbol of QNTM. The consolidation, which is part of the company’s efforts to regain compliance with NASDAQ’s minimum bid price, and name change are subject to approval by the NASDAQ exchange; if approved, the changes will be effective Aug. 15, 2024. These actions have all been approved by company shareholders at the annual general and special meeting of shareholders held on July 22, 2024.

FSD Pharma stock is up on Friday as HUGe ivnestors react to an update on its investment in Celly Nutrition and a new product launch.

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is providing a status report on its investment in Celly Nutrition Corp. A privately held Canadian company, Celly Nu is launching an innovative beverage product designed to assist in expediting alcohol metabolism and faster recovery from alcohol consumption.

TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information. The report, which highlights functional beverage market developments, discusses FSD Pharma’s revolutionary rapid detoxification drink, unbuzzd(TM). The drink helps to rapidly restore mental alertness post-alcohol consumption.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is reporting on the results of its annual general and special meeting of shareholders; the in-person meeting was held on July 22, 2024, in Toronto, Ontario. According to the report, shareholders were represented in person or by proxy at the meeting. Shareholders elected seven directors for the company, with the directors serving until the next annual meeting or until a successor is elected or appointed; the elected directors include Anthony Durkacz, Zeeshan Saeed, Dr. Lakshmi P. Kotra, Adnan Bashir, Dr. Sanjiv Chopra, Michael (Zappy) Zapolin and Dr. Eric Hoskins. In addition, shareholders reappointed MNP LLP as the company’s auditor; approved a share consolidation resolution; approved a special resolution giving board members power to change the company’s name; passed a special resolution approving and ratifying the company’s articles of amendment; and passed an ordinary resolution authorizing the board to approve the issue of additional Class A multiple voting shares.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed an amended and restated material change report. According to the announcement, the report amended the disclosure in Section 5.1 of the original MCR. “The amended and restated material change report is being filed to provide additional disclosure with respect of the private placement offering of Class A multiple voting shares of the company that closed on Dec. 5, 2023,” stated the company in the press release. “The amended and restated MCR can be found on the company’s SEDAR+ profile.”

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that it has partnered with Totaligent Inc. (OTC: TGNT) to assist the company in its efforts to enhance its market awareness. According to the announcement, FSD Pharma retained the services of Totaligent with an objective to “foster productive, continuing dialogues with shareholders and other market participants.” Totaligent brings more than two decades of experience in market-awareness campaigns to the table; the company also has a database of 32 million active investors, which it communicates with through email, SMS, social media, push notification, pay-per-click (“PPC”), search, and digital and print media. The announcement also noted that FSD Pharma issued 650,000 Class B subordinate voting shares in the capital of the corporation to arm’s length creditors; the shares were issued at $0.30 per Class B share and were issued to settle a debt of $195,000. “Totaligent has been engaged for a 30-day term, with either party having the right to terminate the engagement agreement upon providing five business-day notice,” the press release stated. “The contract total is $30,000 to be paid in cash. This contract was signed on June 28, 2024, and is expected to end on July 28, 2024, unless renewed by mutual consent. Totaligent and its principals are arm’s length parties to the company.”

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that the United States District Court for the Eastern District of Pennsylvania ruled in favor of FSD Pharma and is granted its motion for entry of judgment against Dr. Raza Bokhari, the company’s former CEO. The decision awards FSD Pharma several awards, including $147,301.04 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$31,912.55 plus interest at a rate of 4% per annum from Nov. 9, 2022, until the date the judgment is satisfied; C$15,000 plus interest at a rate of 4% per annum from March 1, 2023, until the date the judgment is satisfied; and C$2,814,229.15 plus interest at a rate of 6% per annum from May 7, 2023, until the date the judgment is satisfied. The judgment results from action taken by Bokhari after FSD’s board of directors terminated him. “After years of litigation and an eight-day evidentiary hearing, the arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD’s fees and costs incurred in the arbitration,” stated the press release. “FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.”

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQHUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much hard work designing this MAD trial, we are thrilled that we have received HREC approval, and the trial can now commence,” said FSD Pharma vice president of scientific and clinical affairs Dr. Andrzej Chruscinski in the press release. “This marks an important step in the clinical development of Lucid-21-302 (Lucid-MS).”

FSD Pharma (NASDAQHUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcement, the human ethics review committee (“HREC”) in Australia approved the trial, which is titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A first-in-class, nonimmunomodulatory, neuroprotective compound, Lucid-21-302 offers a unique mechanism of action for the treatment of multiple sclerosis (“MS”). “After much hard work designing this MAD trial, we are thrilled that we have received HREC approval, and the trial can now commence,” said FSD Pharma vice president of scientific and clinical affairs Dr. Andrzej Chruscinski in the press release. “This marks an important step in the clinical development of Lucid-21-302 (Lucid-MS).”